Elite in Hyperthyroidism

Mario Salvi

Milan, IT 
Elite in Hyperthyroidism
Milan, IT 
OverviewLocationsClinical Research

Overview

Mario Salvi practices in Milan, Italy. Mr. Salvi is rated as an Elite expert by MediFind in the treatment of Hyperthyroidism. His top areas of expertise are Graves Disease, Hyperthyroidism, Subacute Thyroiditis, and Severe Acute Respiratory Syndrome (SARS).

His clinical research consists of co-authoring 51 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 47 articles and participated in 2 clinical trials in the study of Hyperthyroidism.

Gender
Male

Locations

Milan, Italy
Other Locations
Brescia, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Other, Biological
Study Phase: Phase 3
Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease
Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Biological
Study Phase: Phase 3
View 1 Less Clinical Trial

51 Total Publications

Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab.
Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab.
Journal: European thyroid journal
Published: November 18, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Salvi's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile